🚨 Bioverge Access Fund 4 is now accepting investors! Leverage Bioverge expertise and back 15 leading healthcare startups through a single investment. Learn more and invest

✨ New Investment Opportunity: Transforming Epilepsy Care 🙇

Invest in Eysz to accelerate personalized treatments with improved patient outcomes for 70M+ epilepsy patients worldwide.


We are pleased to share our newest investment opportunity with you: Eysz, Inc.

Eysz is transforming epilepsy care through development of a proprietary eye-tracking platform that uses AI to passively monitor eye movements, enabling accurate, remote detection of patient seizures and symptoms.

Opportunity Highlights:

  • $5B+ global opportunity with 70M+ patients affected. More people live with epilepsy than with autism, Parkinson's, MS, and cerebral palsy - combined.
  • World-class team and partners at the forefront of Epilepsy care. 
  • Successful 30-patient trial demonstrated accurate, continuous, remote seizure detection. Now enrolling multi-center clinical study blessed by FDA.
  • First Bioverge opportunity open to both accredited and non-accredited investors. Invest before July 27th to secure discounted round terms.

Reserve an Allocation

Investment Memo Preview:

Epilepsy is a debilitating neurological condition characterized by recurring, unprovoked seizures. Despite affecting 1 in 26 people globally, including over 5 million in the U.S. alone, patient outcomes have not meaningfully improved in over 30 years! How could that be?
Looking into the data, what you'd find is...the lack of reliable data is a major part of the problem!
99% of epileptic seizures occur outside of the hospital setting, which means that doctors can't realistically collect seizure data themselves. And since there isn't a reliable way to do this remotely, their best source of data to date has been information reported to them directly from the patient. This is unfortunate because patient-reported seizure data has been determined to be over 50% inaccurate!
Sadly, doctors have only had this to go from when treating their patients. And as a result, treatment selection and dosing has largely been accomplished by trial-and-error up to this point, leading patients to experience more seizures, more side effects, a lower quality of life, and ultimately be less inclined to continue taking their medicine over time.
What is sorely needed is a way for doctors to better understand the extent of patient seizures and objectively measure how they are responding to various treatments.

Eysz has developed a proprietary eye-tracking platform that uses AI to passively monitor eye movements, enabling accurate, remote detection of patient seizures and symptoms.
With Eysz, doctors will be equipped with objective measurements of seizure activity and trends, assisting them with personalized treatment selection and dosing. For patients, this translates to improved quality of life with fewer seizures, side effects, hospitalizations, and expenses. And for the pharma industry, a better understanding of which patients are most likely to benefit from their drugs and fresh incentive to accelerate the development of new precision medicines

Learn More and Invest